Pioglitazone for diabetes prevention in impaired glucose tolerance.

BACKGROUND Impaired glucose tolerance is associated with increased rates of cardiovascular disease and conversion to type 2 diabetes mellitus. Interventions that may prevent or delay such occurrences are of great clinical importance. METHODS We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance. A total of 602 patients were randomly assigned to receive pioglitazone or placebo. The median follow-up period was 2.4 years. Fasting glucose was measured quarterly, and oral glucose tolerance tests were performed annually. Conversion to diabetes was confirmed on the basis of the results of repeat testing. RESULTS Annual incidence rates for type 2 diabetes mellitus were 2.1% in the pioglitazone group and 7.6% in the placebo group, and the hazard ratio for conversion to diabetes in the pioglitazone group was 0.28 (95% confidence interval, 0.16 to 0.49; P<0.001). Conversion to normal glucose tolerance occurred in 48% of the patients in the pioglitazone group and 28% of those in the placebo group (P<0.001). Treatment with pioglitazone as compared with placebo was associated with significantly reduced levels of fasting glucose (a decrease of 11.7 mg per deciliter vs. 8.1 mg per deciliter [0.7 mmol per liter vs. 0.5 mmol per liter], P<0.001), 2-hour glucose (a decrease of 30.5 mg per deciliter vs. 15.6 mg per deciliter [1.6 mmol per liter vs. 0.9 mmol per liter], P<0.001), and HbA(1c) (a decrease of 0.04 percentage points vs. an increase of 0.20 percentage points, P<0.001). Pioglitazone therapy was also associated with a decrease in diastolic blood pressure (by 2.0 mm Hg vs. 0.0 mm Hg, P=0.03), a reduced rate of carotid intima-media thickening (31.5%, P=0.047), and a greater increase in the level of high-density lipoprotein cholesterol (by 7.35 mg per deciliter vs. 4.5 mg per deciliter [0.4 mmol per liter vs. 0.3 mmol per liter], P=0.008). Weight gain was greater with pioglitazone than with placebo (3.9 kg vs. 0.77 kg, P<0.001), and edema was more frequent (12.9% vs. 6.4%, P=0.007). CONCLUSIONS As compared with placebo, pioglitazone reduced the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus by 72% but was associated with significant weight gain and edema. (Funded by Takeda Pharmaceuticals and others; ClinicalTrials.gov number, NCT00220961.).

[1]  R. Bergman,et al.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. , 1981, The Journal of clinical investigation.

[2]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[3]  Y. Miyazaki,et al.  Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician , 2005 .

[4]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[5]  M. Matsuda,et al.  Thiazolidinediones improve beta-cell function in type 2 diabetic patients. , 2007, American journal of physiology. Endocrinology and metabolism.

[6]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[7]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[8]  R. Bain,et al.  Predictors of Progression From Impaired Glucose Tolerance to NIDDM: An Analysis of Six Prospective Studies , 1997, Diabetes.

[9]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[10]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[11]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[12]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[13]  S. Azen,et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.

[14]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[15]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[16]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[17]  S. Fowler,et al.  The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[18]  S. Fowler,et al.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.

[19]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[20]  Devjit Tripathy,et al.  Actos Now for the prevention of diabetes (ACT NOW) study , 2009, BMC endocrine disorders.

[21]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[22]  F. Ovalle.  10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .

[23]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[24]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[25]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[26]  J. Crouse.  Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art Published, JLR Papers in Press, May 16, 2006. , 2006, Journal of Lipid Research.

[27]  S. Yusuf,et al.  The DREAM trial – Authors' reply , 2006, The Lancet.

[28]  W. Rathmann,et al.  Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy , 2008, Diabetes Care.

[29]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[30]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[31]  M. Jensen,et al.  Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. , 2009, The American journal of medicine.

[32]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[33]  R. Klein,et al.  Association of A1C and Fasting Plasma Glucose Levels With Diabetic Retinopathy Prevalence in the U.S. Population , 2009, Diabetes Care.

[34]  R. DeFronzo,et al.  Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance , 2006, Diabetes.

[35]  Bo Zhang,et al.  The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study , 2008, The Lancet.

[36]  Andrew J Weissman,et al.  Intensive diabetes treatment and cardiovascular disease. , 2006, The New England journal of medicine.

[37]  J. Lachin,et al.  Estimators and tests in the analysis of multiple nonindependent 2 x 2 tables with partially missing observations. , 1988, Biometrics.

[38]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[39]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[40]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[41]  T. Buchanan,et al.  Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. , 2006, Diabetes.